Cyclacel Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
12 M |
Public Float |
9.66 M |
Cyclacel Pharmaceuticals Inc. 6% Conv. Pfd. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
335 K |
Public Float |
333.67 K |
Cyclacel Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.65 |
Market Cap |
$10.01 M |
Shares Outstanding |
17.2 M |
Public Float |
12.34 M |
Address |
200 Connell Drive Berkeley Heights New Jersey 07922 United States |
Employees | - |
Website | http://www.cyclacel.com |
Updated | 07/08/2019 |
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. |